NCT03280303: Palbociclib in Real World Practice

NCT03280303
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Serine-Threonine Kinase Inhibitor, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03280303

Comments are closed.

Up ↑